Health IT Analytics September 4, 2018
Jessica Kent

The FDA is seeking to speed up innovations in clinical trials, medical product development, and artificial intelligence using cost-effective strategies and big data.

The FDA is turning to cost-effective strategies and big data to accelerate clinical trial efficiency, medical product development, and innovations in artificial intelligence, according to a recent blog post from FDA Commissioner Scott Gottlieb, MD.

“Our longstanding goal for medical care is to ensure that the right drug or device is delivered to the right patient at the right time. This vision is increasingly possible with the innovative products that are becoming available,” he wrote.

“These new technologies offer transformative opportunities. But they also challenge the US Food and Drug Administration (FDA) to modernize...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: AI (Artificial Intelligence), Big Data, FDA, Govt Agencies, Pharma, Technology, Trends
Related Articles:
FDA wants to boost trial innovation with new center at CDER
Stelara biosimilar from Alvotech, Teva approved by FDA
Scopio Labs Receives FDA Clearance For AI-Driven Bone Marrow Analysis Application
STAT+: Grocers are pushing legislation they claim would enhance food safety. Advocates say it would gut FDA rules
Look Before You Leap - Early Determination Of Product Classification And Regulatory Pathway For FDA-Regulated Products

Share This Article